内脏利什曼病临床药物治疗研究现状  

Current research status of clinical pharmaceutical treatment options for visceral Leishmaniasis

作　　者：袁传杰 杨雪 朱渝 Chuanjie Yuan;Xue Yang;Yu Zhu(Department of Pediatrics,Key Laboratory of Birth Defects and Related Diseases of Women and Children(Sichuan University),Ministry of Education,West China Second University Hospital,Sichuan University,Chengdu 610041,Sichuan Province,China)

机构地区：[1]四川大学华西第二医院儿科、出生缺陷与相关妇儿疾病教育部重点实验室,成都610041

出　　处：《中华妇幼临床医学杂志（电子版）》2022年第4期387-392,共6页Chinese Journal of Obstetrics & Gynecology and Pediatrics(Electronic Edition)

基　　金：四川省科技厅课题(2022YFS0243)。

摘　　要：内脏利什曼病(VL)又被称为黑热病,是人体被利什曼原虫感染所致的播散性原虫病。VL患者的临床表现包括长期发热,肝、脾大,全血细胞减少及进行性贫血与消瘦等。我国治疗VL的临床药物以5价锑剂为主。目前临床治疗VL可供选择的药物种类少。笔者拟就VL患者药物治疗方案的最新研究进展进行阐述,旨在为该病患者的临床治疗提供参考。Visceral Leishmaniasis(VL),also known as Kala-Azar,is a disseminated protozoal infection disease caused by Leishmania.Clinical manifestations of VL patients include chronic fever,hepatosplenomegaly,pancytopenia,progressive anemia and emaciation,etc..In China,penta-valent antimony is the main treatment option for VL patients.At present,there are a few kinds of medicine available for clinical treatment of VL.This article focuses on review latest research progresses of clinical treatment for VL patients so as to provide reference for physicians.

关 键 词：利什曼病 内脏 临床方案 5价锑剂 两性霉素B 巴龙霉素 米替福新 喷他脒 儿童 

分 类 号：R531.6[医药卫生—内科学]